StandardStandard

All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2007 gol. Unknown, 2007.

Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

HarvardHarvard

APA

CBE

MLA

VancouverVancouver

Author

RIS

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2007/1/1

Y1 - 2007/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/FAR%20dasatinib%20CML.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

PB - Unknown

ER -